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Abstract. Background: Because annulated indoles have
almost no representation in the PubChem or MLSMR
databases, an unprecedented class of an indole-based library
was constructed, using the indole aryne methodology, and
screened for antitumor activity. Sixty-six novel 6,7-annulated-
4-substituted indole compounds were synthesized, using a
strategic combination of 6,7-indolyne cycloaddition and cross-
coupling reactions under both Suzuki-Miyaura and Buchwald-
Hartwig conditions, and tested for their effectiveness against
murine L1210 tumor cell proliferation in vitro. Materials and
Methods: Various markers of tumor cell metabolism, DNA
degradation, mitotic disruption, cytokinesis and apoptosis
were assayed in vitro to evaluate drug cytotoxicity. Results:
Most compounds inhibited the metabolic activity of leukemic
cells in a time- and concentration-dependent manner but only
9 of them were sufficiently potent to inhibit L1210 tumor cell
proliferation by 50% in the low-μM range after 2 (IC50: 4.5-
20.4 μM) and 4 days (0.5-4.0 μM) in culture. However, the
antiproliferative compounds that were the most effective at day
4 were not necessarily the most potent at day 2, suggesting
different speeds of action. A 3-h treatment with
antiproliferative annulated indole was sufficient to inhibit, in a
concentration-dependent manner, the rate of DNA synthesis
measured in L1210 cells over a 0.5-h period of pulse-labeling
with 3H-thymidine. Four of the antiproliferative compounds
had weak DNA-binding activities but one compound reduced
the fluorescence of the ethidium bromide-DNA complex by up
to 53%, suggesting that some annulated indoles might directly
interact with double-stranded DNA to disrupt its integrity and
prevent the dye from intercalating into DNA base pairs.
However, all 9 antiproliferative compounds induced DNA
cleavage at 24 h in L1210 cells, containing 3H-thymidine-
prelabeled DNA, suggesting that these antitumor annulated
indoles might trigger an apoptotic pathway of DNA
fragmentation. Indeed the antiproliferative annulated indoles
caused a time-dependent increase of caspase-3 activity with a
peak at 6 h. Interestingly, the compounds with the most potent
antiproliferative IC50 values at day 2 were consistently the
most effective at inhibiting DNA synthesis at 3 h and inducing
DNA fragmentation at 24 h. After 24-48 h, antiproliferative
concentrations of annulated indoles increased the mitotic
index of L1210 cells and stimulated the formation of many bi-
nucleated cells, multi-nucleated cells, apoptotic cells and
micronuclei, suggesting that these antitumor compounds might
enhance mitotic abnormality, induce chromosomal damage or
missegregation, and block cytokinesis to induce apoptosis.
Conclusion: Although annulated indoles may have interesting
bioactivity, novel derivatives with different substitutions must
be synthesized to elucidate structure-activity relationships,
identify more potent antitumor lead compounds, and
investigate their molecular targets and mechanisms of action. 
Indole arynes or indolynes were discovered and reported as a
completely new class of reactive aryne intermediate (1-5). An
unprecedented 93-member library of 6,7-annulated-4-
substituted indoles was constructed, using a strategic
combination of 6,7-indolyne cycloaddition and cross-coupling
reactions under both Suzuki-Miyaura and Buchwald-Hartwig
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conditions (6). This work may represent the first example of
library development that employs the indole aryne
methodology (6). The 4 steps of the synthetic process,
showing cycloaddition at the 6,7 position, followed by cross-
coupling at the C4 position, are summarized in Figure 1. 1)
The main 4,6,7-tribromoindole scaffold was synthesized by
the Bartoli reaction (7, 8). 2) The N-methyl-4,6,7-
tribromoindole scaffold was treated with n-butyllithium to
generate the 6,7-indole aryne which reacted with both
cyclopentadiene (X=CH2) and furan (X=O) to give the
respective Diels-Alder cycloadducts in high yields. 3) The
olefin (alkene) in the cycloadduct had to be reduced
quantitatively with diimide prior to cross-coupling in order to
produce higher yields (9). 4) The 4-Br was reacted either with
various boronic acids under a carefully prescribed set of
conditions to give the Suzuki-Miyaura cross-coupled products
or with various commercially-available secondary amines
under a carefully prescribed set of conditions to give the
Buchwald-Hartwig cross-coupled products (6). The reason
such annulated indoles were synthesized is that they have
almost no representation in the NIH PubChem and Molecular
Library Small Molecule Repository (MLSMR) databases and
their biological properties have not been fully evaluated and
exploited. The only exceptions are a few biologically active
natural products, such as trikentrins (10), which are
antibacterial agents, herbindoles (11), which possess
cytotoxic and anti-feedant properties, teleocidins (12), which
are tumor promoters used to study multistage carcinogenesis,
and nodulisporic acids (13), which have antiparasitic activity.
Annulated indoles were therefore predicted to have unique
chemical property space characteristics and a good
probability of exhibiting interesting biological activity (6).
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Figure 1. First example of library development that employs the indole aryne methodology to construct 6,7-annulated-4-substituted indole compounds.
Top: Bartoli route to prepare the N-methyl-4,6,7-tribromoindole scaffold. Bottom: Selective generation of 4-bromo-6,7-indole aryne, and strategic
combination of 6,7-indolyne cycloaddition and cross-coupling reactions under both Suzuki-Miyaura and Buchwald-Hartwig conditions to construct
polycyclic indole libraries.
Hence, a total of 66 newly-synthesized 6,7-annulated-4-
substituted indoles were evaluated for their antiproliferative
activity in rapidly growing suspension cultures of L1210
leukemia cells, using tests of metabolic activity, DNA
degradation, mitotic disruption, cytokinesis and apoptosis in
vitro (14, 15).
Materials and Methods
Drug treatment, cell culture and proliferation assay. Solutions of
synthetic 6,7-annulated-4-substituted indoles and known anticancer
drugs used as positive controls (all from Sigma-Aldrich, St. Louis,
MO, USA) were dissolved and serially-diluted in dimethyl sulfoxide
(DMSO). Suspension cultures of murine L1210 lymphocytic
leukemia cells (ATCC, Manassas, VA, USA) were incubated at 37˚C
in a humidified atmosphere containing 5% CO2 and maintained in
continuous exponential growth by twice-a-week passage in RPMI
1640 medium supplemented with 10% fetal bovine calf serum (FCS;
Atlanta Biologicals, Norcross, GA, USA) and penicillin (100 IU/ml)-
streptomycin (100 μg/ml). L1210 cell suspensions were grown in
triplicate in 48-well Costar cell culture plates for 2 and 4 days in the
presence or absence (control) of serial concentrations of synthetic 6,7-
annulated-4-substituted indoles to evaluate their antiproliferative
activity. Since compounds were supplemented to the culture medium
in 1-μl aliquots, the concentrations of vehicle in the final incubation
volume (0.5 ml) never exceeded 0.2% and did not interfere with the
data. Decreasing concentrations of cells, such as 45,000 and 2,500
L1210 cells/0.5 ml/well, were initially plated in triplicate at time 0 in
order to collect control samples with approximately equal cell
densities after 2 and 4 days in culture, respectively (14, 15). The
proliferation of control and drug-treated tumor cells was assessed
from their mitochondrial ability to bioreduce the 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) reagent (Promega, Madison, WI, USA) in the
presence of phenazine methosulfate (PMS; Sigma) into a water-
soluble formazan product that absorbs at 490 nm (16). After 2 or 
4 days in culture, control and drug-treated L1210 cell samples were
further incubated at 37˚C for 2 h in the dark in the presence of 
0.1 ml of MTS:PMS (2:0.1) reagent and their relative metabolic
activity was estimated by recording the absorbance at 490 nm, using
a Cambridge model 750 automatic microplate reader (Packard,
Downers Grove, IL, USA) (14, 15). Blank values for culture medium
supplemented with MTS:PMS reagent in the absence of cells were
subtracted from the results. Data of all biochemical experiments were
analyzed using the Student’s t-test with the level of significance set
at p<0.05.
DNA synthesis. To estimate the rate of DNA synthesis, L1210 cells
were re-suspended in fresh FCS-containing RPMI 1640 medium at
a density of 0.5×105 cells/0.5 ml, incubated at 37˚C for 2.5 h in the
presence or absence (control) of drugs and then pulse-labeled for an
additional 30 min with 1 μCi of [methyl-3H]thymidine (52
Ci/mmol; GE Healthcare-Amersham, Piscataway, NJ, USA) (14,
15). The incubations were terminated by the addition of 2 ml of
10% trichloroacetic acid (TCA). After holding on ice for 15 min,
the acid-insoluble material was recovered over Whatman GF/A glass
microfiber filters and washed thrice with 2 ml of 5% TCA and twice
with 2 ml of 100% EtOH. After drying the filters, the radioactivity
bound to the acid-precipitable material was determined by liquid
scintillation counting (LSC) in 6 ml of Bio-Safe NA (Research
Products International, Mount Prospect, IL, USA) (14, 15).
DNA binding and fragmentation assays. An ethidium bromide (EB)
displacement assay was used to assess the eventual DNA-binding
potencies of 6,7-annulated-4-substituted indoles, based on the IC50
concentrations of drugs that cause a 50% reduction in the fluorescence
of the DNA-EB complex at 525 nm excitation/600 nm emission (17).
The fluorescence of EB, which is extremely low when unbound in
water, is boosted 25-fold after binding and intercalating in the
hydrophobic environment of the intact double-stranded DNA. Since a
highly fluorescent complex is formed within milliseconds between
DNA and EB, any drug directly binding to and/or damaging DNA
would disrupt EB intercalation and compromise the fluorescence of
this EB-DNA complex. The reaction mixtures (200 μl), containing
final concentrations of 20 μg/ml calf thymus (ct) DNA (Sigma) and 
1 μg/ml EB (Sigma) in 5 mM Tris-HCl buffer, pH 7.6, with 0.5 mM
EDTA, were pipetted into 96-well Costar white opaque polystyrene
assay plates and, after incubation in the presence or absence (control)
of drugs for 30 min at room temperature, the fluorescence of the EB-
DNA complex was detected at 525 nm excitation and 600 nm
emission, using a Cary Eclipse Fluorescence Spectrophotometer
equipped with a microplate reader accessory (Varian, Walnut Creek,
CA, USA) (14, 15). Drug-induced DNA cleavage was determined by
intact chromatin precipitation, using L1210 cells which were pre-
labeled with 1 μCi of [3H]thymidine for 2 h at 37˚C, washed with 3×1
ml of ice-cold Ca2+/Mg2+-free Dulbecco’s phosphate-buffered saline
(PBS), collected by centrifugation, resuspended in fresh medium at a
density of 1.2×106 cells/ml, and then incubated at 37˚C for 24 h in the
presence or absence of drugs (14, 15). After centrifugation at 200 ×g
for 10 min to discard the drugs and wash the cells, the cell pellets were
lysed for 20 min in 0.5 ml of ice-cold hypotonic lysis buffer (10 mM
Tris-HCl, pH 8.0, 1 mM EDTA and 0.2% Triton X-100), and
centrifuged at 12,000 ×g for 15 min to collect the supernatants. The
radioactivity in the supernatants (detergent-soluble low molecular
weight DNA fragments) and the pellets (intact chromatin DNA) was
determined by LSC. Before being counted in 6 ml of Bio-Safe NA,
the intact pelleted chromatin was incubated for 2 h at 60˚C in the
presence of 0.6 ml of NCS tissue solubilizer (Amersham) (14, 15).
Fluorogenic assay of caspase-3 activity. Control and drug-treated
L1210 cells (1.2×106/ml) were incubated for various periods of time
at 37˚C, collected by centrifugation (200 g × 10 min), and washed
with 1 ml of ice-cold PBS. The cell pellets were resuspended in 
120 μl of chilled 10 mM Hepes buffer, pH 7.4, containing 100 mM
NaCl, 100 mM KCl, 5 mM MgCl2, 1 mM EDTA, 10 mM EGTA,
10% sucrose, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM
dithiothreitol (DTT), and 100 μM digitonin, and were lysed for 10
min on ice. The cell lysates were centrifuged (14,000 ×g for 20 min)
at 4˚C to precipitate cellular debris and 100-μl aliquots of the clear
supernatants were stored at –70˚C overnight (14, 18-20). The
caspase-3-like activities of the lysates were determined in reaction
mixtures that contained 50 μl of lysis buffer (blank) or supernatant
(control or drug-treated samples) and 50 μl of reaction buffer 
(100 mM Hepes, pH 7.5, containing 1 mM EDTA, 10 mM EGTA,
10% sucrose, and 10 mM DTT) and that were initiated by the
addition of 5-μl aliquots of the specific 1 mM benzyloxycarbonyl
(z)-Asp-Glu-Val-Asp (DEVD)-7-amino-4-trifluoromethylcoumarin
(AFC) stock of AFC-substrate conjugate (Calbiochem, EMD
Biosciences, San Diego, CA, USA) (14, 18-20). After incubation for
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1 h at 37˚C in 96-well Costar white opaque polystyrene assay plates,
the fluorescence of the free AFC released upon proteolytic cleavage
of the substrate by caspase-3 was detected at 400-nm excitation and
505-nm emission, using a Cary Eclipse Fluorescence
Spectrophotometer with a microplate reader. Arbitrary fluorescence
units were quantified with reference to calibration curves ranging
from 0.1 to 1.2 nmol of AFC (from Sigma), the protein
concentrations of the supernatants were determined using the BCA
Protein Assay Kit (Pierce, Rockford, IL, USA), and the DEVD-
specific cleavage activities of the samples were expressed as nmol
of AFC released/mg of protein (14, 18-20).
Mitotic index and abnormalities. To determine the mitotic index,
L1210 cells (0.5×106/0.5 ml of FCS-containing RPMI 1640
medium) were incubated in triplicate for various periods of time at
37˚C in the presence or absence (control) of serial concentrations
of experimental drugs or known microtubule-disrupting agents,
collected by centrifugation (200 ×g for 10 min), and resuspended in
1 ml of hypotonic 75 mM KCl for 20 min at 4˚C. After fixation in
1 ml of MeOH:acetic acid (3:1), the final cell pellets were collected
by centrifugation, resuspended in 75 μl of MeOH:acetic acid (3:1),
dispensed onto glass slides, air dried, and stained by spreading 40 μl
of 0.1% crystal violet under a coverslip (14, 15). Mitotic figures
with condensed chromosomes were identified microscopically and
published criteria were followed to score binucleated cells (BNCs),
multinucleated cells (MULTI) and micronuclei (MNi) (21).
Cytokinesis-blocked BNCs contained either 2 separate nuclei of
equal size, 2 nuclei that touched or overlapped with distinct nuclear
boundaries, or 2 nuclei that were linked by a small nucleoplasmic
bridge (21). Viable cells with 3 (trinucleated) or 4 (quadrinucleated)
distinct nuclei were scored as typical MULTI cells (21). Dot-like
chromatin-containing structures in the cytoplasm, at least 1/3
smaller than the main nucleus, surrounded by a membrane either
separated from or marginally overlapping the main nucleus, and
having the same staining as the main nucleus were scored as MNi
containing either a whole chromosome or an acentric chromosomal
fragment (21). The frequencies of BNCs, MULTI cells and MNi
were used to estimate the ability of cytotoxic or genotoxic
(mutagenic or clastogenic) drugs to block cytokinesis and induce
chromosomal damage or missegregation (21). The % of cells in
mitosis or with 2 nuclei, 3-4 nuclei and MNi were determined
microscopically by counting a total of at least 2,000 cells/slide and
the mitotic, BNC and MULTI cell indexes were calculated as % of
mitotic figures or BNC and MULTI cells in drug-treated cultures/%
of mitotic figures or BNC and MULTI cells in vehicle-treated
controls (14, 15, 21).
Results
Inhibition of tumor cell proliferation. All 66 synthetic 6,7-
annulated-4-substituted indoles tested, inhibited the
proliferation of suspension cultures of murine L1210
lymphocytic leukemia cells after 4 days in vitro (Table I). It
would be unfeasible to show the structures and antitumor
effects of all 66 compounds but, in summary Table I, groups
of 6,7-annulated-4-substituted indoles are ranked according
to the range of their concentrations required to inhibit the
mitochondrial ability of L1210 cells to metabolize the
MTS:PMS reagent by 50% after 2 days in culture. Only 3
compounds have no effect or inhibit tumor cell proliferation
at day 2 by less than 50%, at the highest 156.25 μM
concentration tested but the other groups of compounds have
increasing antiproliferative activities with IC50 values in the
50-150, 40-50, 30-40, 20-30, 10-20 and less than 10 μM
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Table II. Antiproliferative activity of synthetic 6,7-annulated indole
compounds in L1210 tumor cells in vitro.
Compounds IC50 values (μM)a
in L1210 cells at
Day 2 Day 4
KU-69 13.2±0.5  0.5±0.02
KU-70 5.8±0.2  2.8±0.2
KU-72 7.8±0.6  2.0±0.2
KU-80 7.0±0.4  2.4±0.2
KU-87 16.1±0.6  1.1±0.1
KU-95 20.4±0.7  1.4±0.1
KU-96 4.9±0.2  2.3±0.1
KU-113 6.1±0.2  4.0±0.1
KU-191 4.5±0.1  2.7±0.1
Concentrations of novel synthetic indole-based compounds required to
inhibit by 50% (IC50 values) the metabolic activity of L1210 leukemic
cells, using the MTS:PMS assay after 2 or 4 days of culture in vitro.
IC50 values (μM) were calculated from linear regression of the slopes of
the log-transformed concentration-survival curves. aMeans±SD (n=3).
Table I. 66 Newly-synthesized 6,7-annulated indole compounds screened
for the inhibition of L1210 leukemic cell proliferation in vitro.
Number of Range of IC50 values (μM) 
compounds in L1210 cells at
tested
Day 2 Day 4
3 compounds NAa 18.7-137.8
5 compounds 51.9-154.6 22.3-37.4 
5 compounds 42.0-49.6 24.9-29.4
8 compounds 31.3-37.8 16.5-25.4
18 compounds 20.0-29.5 1.4-20.4
18 compounds 10.8-19.6 0.5-13.4
9 compounds 4.9-9.3 2.0-6.9
Concentrations of novel synthetic indole-based compounds required to
inhibit by 50% (IC50 values) the metabolic activity of L1210 leukemic
cells, using the MTS:PMS assay after 2 or 4 days of culture in vitro.
IC50 values (μM) were calculated from linear regression of the slopes
of the log-transformed concentration-survival curves. Groups of
compounds are ranked according to the range of their IC50 potencies at
day 2. aValues are not available because the compounds have either no
effect or decrease tumor cell proliferation by less than 50% at the
highest 156.25 μM concentration tested.
ranges (Table I). For individual compounds, the IC50 values
at day 4 are always lower than values at day 2 because the
magnitude of inhibition between the control cells that keep
growing exponentially and the drug-treated cells that are
inhibited keeps increasing over time. Hence, the 9
compounds that had the best combinations of
antiproliferative IC50 values at day 2 and 4 were selected for
further studies and their chemical structures and abilities to
inhibit the metabolic activity of L1210 cells are detailed in
Figure 2 and Table II, respectively. For simplification, the
full KUC identification numbers of the compounds
synthesized at the NIH Center of Excellence, in Chemical
Methodologies and Library Development, at the University
of Kansas (KU-CMLD) have been logically abbreviated in
the present article: for example, KUC107069 is KU-69,
KUC107072 is KU-72, etc… (Figure 2). Interestingly,
among these 9 most potent antiproliferative compounds, 8
were from the Buchwald-Hartwig cross-coupled products
(i.e. those that have an amine at the C-4 position of the
indole) and just one (KU-191) came from the Suzuki-
Miyaura series of library members (Figure 2). All these 9
antiproliferative 6,7-annulated-4-substituted indoles have
promising antitumor effects in the low μM range but it
should be noted that the compounds that seem to be the most
effective at day 4 are not necessarily the ones the most potent
at day 2 (Table II). Full concentration-response curves
indicate that the inhibitions of tumor cell growth by
antiproliferative compounds KU-69, KU-87 and KU-95, which
are the most effective at day 4, begin around 102-256 nM and
become maximal or near maximal around 10-25 μM (Figure 3).
This is an example of 3 compounds that have excellent
antiproliferative activities at day 4 but much weaker
concentration-dependent inhibitory effects at day 2, so there
is an unusually wide gap between their IC50 values at days 2
and 4 (Figure 3). In contrast, the concentration-dependent
inhibitions of tumor cell growth by KU-70, KU-80 and KU-
96 illustrate 3 compounds that may not be the most potent at
day 4 but have already excellent antiproliferative activities at
day 2 so the gap is much smaller between their
antiproliferative IC50 values, which are almost similar at
days 2 and 4 (Figure 4). Synthetic 6,7-annulated-4-
substituted indoles, therefore, might differ in both
antiproliferative potencies and speeds of action. However,
when tested as positive controls in the same experiments,
established anticancer drugs like daunorubicin (DAU) and
mitoxantrone (Mitox) inhibited the growth of L1210 tumor
cells at lower nM concentrations (data not shown). 
Inhibition of DNA synthesis. With one exception, a 3-h period
of incubation is sufficient for the antiproliferative 6,7-
annulated-4-substituted indole compounds to inhibit the
incorporation of [3H]thymidine into the DNA used to assess
the rate of DNA synthesis over a 30-min period of pulse-
labeling in L1210 tumor cells in vitro (Figure 5). Interestingly,
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Figure 2. Chemical structures and identification numbers of the most effective antiproliferative 6,7-annulated-4-substituted indole compounds tested
for their antitumor effects in L1210 cells in vitro.
KU-70, KU-80 and KU-96, the compounds with some of the
best antiproliferative IC50 values at day 2 (Table II) are also
the best inhibitors of DNA synthesis at 3 h (Figure 5), whereas
KU-69, KU-87 and KU-95, the compounds with the worst
antiproliferative IC50 values at day 2 (Table II) have no or very
little inhibitory effects on DNA synthesis at 3h (Figure 5). At
25 μM, KU-70, KU-80 and KU-96 can match the ability of
256 nM Mitox to inhibit DNA synthesis by more than 80%,
but are still 100-times weaker than this known anti-cancer
drug used as a positive control in the experiments (Figure 5).
Increasing concentrations of KU-70 and KU-80, which have
good antiproliferative IC50 values at 2 days (Table II), totally
inhibit the ability of tumor cells to synthesize DNA after 3 h
(Figure 6). These concentration-dependent inhibitions of DNA
synthesis by KU-70 and KU-80 are maximal around 25-62.5
μM and characterized by IC50 values of 6.4 and 13.0 μM,
respectively (Figure 6). However, under similar experimental
conditions, Mitox inhibits DNA synthesis in L1210 cells with
an IC50 value of 142 nM (data not shown). 
DNA binding and fragmentation. High concentrations of
antiproliferative 6,7-annulated-4-substituted indoles and
reference anticancer drugs were evaluated for their DNA-
binding affinity in a cell-free system, using the classic EB
displacement assay to identify intercalating or non-
intercalating drugs that destabilize the DNA double helix. As
expected, positive controls of 8 μM Mitox, 50 μM
actinomycin D (Act-D) and 125 μM amsacrine (m-AMSA;
4’-[9-acridinylamino]methanesulfon-m-anisidide), which
destabilize double-stranded ctDNA to prevent or disrupt EB
intercalation, almost totally suppress the fluorescence of the
EB-DNA complex (inhibition by 89.7, 84.2 and 73.8%,
respectively) (Figure 7). Among our 9 antiproliferative
annulated indoles, 4 compounds had no significant effect and
4 other compounds inhibited the fluorescence of the EB-DNA
complex by only 12.4-14.9% when tested at 312.5-781.25 μM
(data not shown). KU-80, which had a good antiproliferative
IC50 value at day 2 (Table II and Figure 4) and was one of
the best inhibitors of DNA synthesis at 3 h (Figures 5 and 6),
was the only compound that inhibited the fluorescence of the
EB-DNA complex in a concentration-dependent manner, with
up to 52.6% inhibition at the highest 1,953.125 μM
concentration tested (Figure 7). However, under similar
experimental conditions, the concentration-dependent
inhibitions of EB binding to DNA by Mitox, Act-D and m-
AMSA have IC50 values of 1.2, 3.4 and 31.0 μM, respectively
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Figure 3. Comparison of the ability of serial concentrations (plotted on a
logarithmic scale) of KU-69 (, ), KU-87 (, ) and KU-95 (, ) to
inhibit the metabolic activity of L1210 tumor cells at days 2 (open
symbols) and 4 (solid symbols) in vitro. L1210 cell proliferation results
were expressed as % of the net absorbance of MTS/formazan after
bioreduction by vehicle-treated control cells after 2 (A490 nm=1.112±0.048)
and 4 (A490 nm=1.177±0.051) days in culture (100±4.3%, striped area).
The blank values (A490 nm=0.432 at day 2 and 0.434 at day 4) for cell-free
culture medium supplemented with MTS:PMS reagent were subtracted
from the results. Bars: means±SD (n=3). aNot different from respective
controls; bp<0.05, cp<0.01 and dp<0.005, lower than respective controls.
Figure 4. Comparison of the ability of serial concentrations (plotted on
a logarithmic scale) of KU-70 (, ), KU-80 (, ) and KU-96 (,
) to inhibit the metabolic activity of L1210 tumor cells at days 2 (open
symbols) and 4 (solid symbols) in vitro. The conditions of the
experiment and the determination of the results were identical to those
of Figure 3. Vehicle-treated control cells after 2 and 4 days: 100±4.3%,
striped area. Bars: means±SD (n=3). aNot different from respective
controls; bp<0.05, cp<0.025, dp<0.01 and ep<0.005, lower than
respective controls.
(data not shown). Hence, only a few of the antiproliferative
annulated indoles might have weak direct interactions with
double-stranded ctDNA to disrupt its structural and functional
integrity and prevent the dye from intercalating into DNA
base pairs. The abilities of our 9 antiproliferative annulated
indoles to induce DNA fragmentation at 24 h were assessed
and compared to those of DAU and Mitox, using L1210 cells
containing 3H-thymidine-prelabeled DNA to detect low
molecular weight DNA fragments after intact chromatin
precipitation (Figure 8). As compared to untreated control
tumor cells where there is only 3.8% of DNA fragmentation,
anti-cancer treatments that induce DNA cleavage and
apoptosis like 1.6 μM DAU and 0.256 μM Mitox respectively
produce 11.6 and 24.0% of DNA fragmentation at 24 h and
are used as positive controls in these experiments (Figure 8).
When tested at 25 μM, all 9 of our antiproliferative annulated
indoles substantially raised the levels of DNA fragmentation
in L1210 cells at 24 h (Figure 8). Again, KU-80 (10.7% DNA
fragmentation), KU-96 (21.7% DNA fragmentation) and KU-
191 (14.6% DNA fragmentation), the compounds that are
some of the most effective inhibitors of tumor cell
proliferation at day 2 (Table II) and DNA synthesis at 3 h
(Figure 5), clearly match the levels of DNA fragmentation
caused by the lower concentrations of DAU and/or Mitox
tested (Figure 8). Moreover, full concentration-response
curves clearly show that, above 25 μM, KU-80, KU-96 and
KU-191 are capable of producing huge 25-50% levels of
DNA fragmentation (Figure 9). Even though they might be,
on an equimolar concentration basis, less cytotoxic than
known anti-cancer drugs, some of these antiproliferative
annulated indoles are also likely to induce the
internucleosomal fragmentation of DNA at 24 h, which is the
ultimate marker of apoptosis in DAU- and Mitox-treated
tumor cells.
Activation of effector caspase-3. Since the activation of
caspase-3 is required to trigger the internucleosomal
fragmentation of DNA by endonucleases, the annulated
indole treatments shown to induce DNA fragmentation at 
24 h were tested for their ability to stimulate this key post-
mitochondrial effector caspase in L1210 cells. The
hypothesis that the caspase activation cascade is linked to
apoptotic DNA fragmentation at 24 h is substantiated by the
fact that 62.5 μM KU-80, 62.5 μM KU-96, 1.6 μM DAU and
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Figure 5. Comparison of the ability of 25 μM concentrations of the
antiproliferative KU-69, KU-70, KU-72, KU-80, KU-87, KU-95, KU-96,
KU-113 and KU-191 compounds to inhibit the rate of incorporation of
[3H]thymidine into DNA measured in L1210 cells over 30 min following
a 3-h period of incubation at 37˚C in vitro. The magnitude of DNA
synthesis inhibition caused by 0.256 μM mitoxantrone (Mitox) was used
as a positive control. DNA synthesis in vehicle-treated control cells (C)
at 37˚C was 20,387±1,325 cpm (100±6.5%). The blank value (766±43
cpm) for control cells incubated and pulse-labeled at 2˚C with 1.5 μCi of
[3H]thymidine has been subtracted from the results. Bars: means±SD
(n=3). aNot different from control; bp<0.025, less than control.
Figure 6. Comparison of the ability of serial concentrations (logarithmic
scale) of the antiproliferative KU-70 () and KU-80 () compounds to
inhibit the rate of incorporation of [3H]thymidine into DNA measured in
L1210 cells over 30 min following a 3-h period of incubation at 37˚C in
vitro. The conditions of the experiment and the determination of the results
were identical to those of Figure 5. DNA synthesis in vehicle-treated
control cells at 37˚C: 100±6.5%, striped area. Bars: means±SD (n=3).
aNot different from control; bp<0.05 and cp<0.025, less than control.
0.64 μM Mitox all maximally induce, in a time-dependent
manner, caspase-3 activity in L1210 cells (Figure 10).
Interestingly, the activations of caspase-3 by KU-80 and KU-
96 are noticeable as early as 3 h and respectively peak at
290.2 and 464.7% of the control after 6 h before slowly
declining back towards basal levels between 12-24 h (Figure
10). That KU-80 induces caspase-3 activity to a lesser degree
than KU-96 at 6 h (Figure 10) is consistent with the fact that
KU-80 also produces less DNA fragmentation than KU-96
at 24 h (Figures 8 and 9). In contrast, the activations of
caspase-3 by DAU and Mitox begin around 12 h and
respectively peak at 605.9 and 379.2% of the control after
24 h (Figure 10), a finding that has already been observed in
L1210 cells (14) and differ from the peak of DAU-induced
caspase-3 activity reported at 6 h in human HL-60
promyelocytic leukemia cells (19). Different concentrations
of drugs causing different ratios of cytostatic:cytotoxic
effects might be responsible for such different sequences of
apoptotic protease activations in different tumor cell lines.
Mitotic index and abnormalities. Microscopic studies were
conducted to determine whether L1210 tumor cells treated for
various periods of time with increasing concentrations of
antiproliferative annulated indoles might undergo mitotic
disruption. Control populations of L1210 tumor cells incubated
in the absence of drugs contain only 0.42% of mitotic cells and
2.73% of BNCs. Known microtubule-disrupting agents like
vincristine (VCR) and taxol were used as positive controls in
these experiments. VCR blocks tubulin polymerization and
microtubule assembly, whereas taxol lowers the critical
concentration of free tubulin required to promote
polymerization and blocks microtubule disassembly. Such
antimitotic anticancer drugs, therefore, block cell-cycle
progression in M-phase and dramatically increase the % of
mitotic cells at 24 and 48 h: by 22.1- and 54.2-fold for 
0.05 μM VCR and by 9.1- and 22.5-fold for 0.05 μM taxol
(Figure 11A). Under similar conditions, increasingly
antiproliferative concentrations of KU-69 also block mitosis,
especially at 24 h in response to 1.6, 4 and 10 μM
concentrations of KU-69, which respectively produce 9.1-,
11.1- and 8.3-fold increases in the % of mitotic cells (Figure
11A). This would suggest some microtubule disruption but the
effect of KU-69 seems to decline at 48 h and for the highest
25 μM concentration tested (Figure 11A). VCR and taxol also
increase by little the % of BNCs: by 2.8-fold for VCR at 48 h
and by 6.9- and 3.9-fold for taxol at 24 and 48 h (Figure 11B).
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Figure 7. Comparison of the ability of 8 μM mitoxantrone (Mitox), 
50 μM actinomycin D (Act-D), 125 μM m-amsacrine (Amsa) and serial
concentrations of antiproliferative KU-80 compound to inhibit the
binding of EB to double-stranded ctDNA. Results were expressed as %
of the control (C) fluorescence of the EB-DNA complex in the absence
of drug at 525 nm excitation and 600 nm emission (162.1±5.3 arbitrary
units; 100±3.3 %). The background of EB fluorescence in the absence of
DNA (26.3±1.0 arbitrary units) was subtracted from the results. Bars:
means±SD (n=3). aNot different from control; bp<0.05, cp<0.025 and
dp<0.005, smaller than control.
Figure 8. Comparison of the ability of 25 μM concentrations of the
antiproliferative KU-69, KU-70, KU-72, KU-80, KU-87, KU-95, KU-
96, KU-113 and KU-191 compounds to induce DNA fragmentation at
24 h in L1210 cells containing 3H-prelabeled DNA in vitro. The levels of
DNA fragmentation caused by 1.6 μM daunorubicin (DAU) and 0.256 μM
mitoxantrone (Mitox) were used as positive controls. The results were
expressed as [cpm in supernatant/(cpm in supernatant + pellet)] x 100
at 24 h. For vehicle-treated control (C) tumor cells (3.83±0.84% DNA
fragmentation), the supernatant (DNA fragments) was 2,096±126 cpm
and the pellet (intact DNA) was 52,628±3,368 cpm. Bars: means±SD
(n=3). ap<0.05 and bp<0.025, greater than control.
But increasing 4, 10 and 25 μM concentrations of KU-69
respectively produce huge 14.1-, 24.7- and 36.5-fold increases
in the % of BNCs, uniquely at 24 h, indicating that they rapidly
induce molecular events that block the process of cytokinesis in
proliferating tumor cells (Figure 11B). VCR at 48 h and taxol
at 24 and 48 h respectively increase by 15.2- and 10.6-29.4-
fold the % of MULTI cells (Figure 12A) and respectively
induce the formation of 0.49 and 7.56-0.70% of cells with MNi
(Figure 12B), as compared to controls where those figures are
extremely rare: 0.34% of MULTI cells and 0.06% of cells with
MNi in vehicle-treated L1210 tumor cells. Under similar
conditions, KU-69 also produces concentration-dependent
increases in the % of MULTI cells and cells with MNi that
match or surpass the effects of VCR and taxol, suggesting that
these antiproliferative annulated indoles might enhance mitotic
abnormalities, induce chromosomal damage or missegregation,
and block cytokinesis. For instance, after 48 h, treatments with
10 and 25 μM KU-69 respectively cause 19.4- and 25.2-fold
increases in the % of MULTI cells (Figure 12A) and induce
the formation of 2.51 and 2.85% of cells that contain MNi
(Figure 12B). It should be noted that the huge % of KU-69-
induced BNCs observed at 24 h dramatically drops at 48 h
(Figure 11B) while the % of KU-69-induced MULTI cells
increases dramatically from 24 to 48 h (Figure 12A), an effect
which is also apparent in response to taxol. This is consistent
with the fact that drug-treated cells with disrupted microtubule
kinetics escape from mitosis without cytokinesis and proceed
as BNCs to the next cell cycle and round of DNA synthesis to
form polynucleated and polyploid cells with 3-4 nuclei, which
eventually die (21, 22). Hence, it is logical that the huge
number of BNCs formed at 24 h drops at 48 h as these BNCs
re-enter the cell cycle and are increasingly transformed into
MULTI cells between 24 and 48 h. BNCs, therefore, do not
disappear but simply evolve into MULTI cells. Finally, as
compared to control L1210 tumor cells where the presence of
nucleoplasmic bridges (NPBs) (0.002%) and nuclear buds
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Figure 9. Comparison of the ability of serial concentrations (logarithmic
scale) of the antiproliferative KU-80 (), KU-96 () and KU-191 ()
compounds to induce DNA fragmentation at 24 h in L1210 cells,
containing 3H-prelabeled DNA in vitro. The conditions of the
experiment and the determination of the results were identical to those
in Figure 8. DNA fragmentation in vehicle-treated control tumor cells:
3.83±0.84%, striped area. Bars: means±SD (n=3). aNot different from
control; bp<0.05 and cp<0.025, greater than control.
Figure 10. Fluorogenic assay of effector caspase activation in drug-
treated L1210 cells. Comparison of the time-dependent inductions of
caspase-3-like protease activity by 0.64 μM mitoxantrone (, Mitox), 1.6
μM daunorubicin (, DAU), 62.5 μM KU-80 () and 62.5 μM KU-96
() in L1210 cells, incubated for 3-24 h in vitro. Results are expressed as
percentage of DEVD cleavage activity in vehicle-treated control tumor
cells (4.06±0.36 nmol AFC released/mg protein, 100±8.9%, striped area)
at each time point tested. Bars: means±SD (n=3). aNot different from
control; bp<0.025 and cp<0.005, greater than control.
(NBUDs) (0.006%) is extremely rare, treatments with 1.6, 4,
10 and 25 μM KU-69 respectively increased by 16.5-, 24.3-,
24.9- and 194.1-fold the % of tumor cells with NPBs and by
6.4-, 27.1-, 31.4- and 80.4-fold the % of cells with NBUDs
(data not shown). Control populations of L1210 tumor cells
incubated for 48 h in the absence of drugs contain only 0.046%
of cells with 5 or more small nuclear structures, which is a
microscopic evidence of nuclear fragmentation into smaller
apoptotic chromatin bodies within an intact cytoplasm and
cytoplasmic membrane (21). Using such criteria, treatments
with 1.6, 4, 10 and 25 μM KU-69, respectively, increased by
3.5-, 6.9-, 9.5- and 45.9-fold the % of microscopically visible
apoptotic tumor cells at 48 h (data not shown), confirming the
results of our caspase-3 and DNA fragmentation studies. 
Discussion
Since annulated indole structures are virtually unknown, we
have exploited our ability to effect a tandem indole aryne
cycloaddition/cross-coupling sequence of reactions with
polybromoindole scaffolds to address this important gap in
the literature. Using this tactic with the 4,6,7-tribromoindole
platform (readily-obtained in scale via the Bartoli indole
synthesis), for example, resulted in the formation of a 93-
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Figure 11. Comparison of the effects of the antiproliferative KU-69
compound, vincristine (VCR) and taxol on the frequency of mitotic
figures (A) and binucleated cells (BNCs) (B) in L1210 tumor cells in
vitro. L1210 cells were incubated in triplicate for 24 (open columns)
and 48 h (closed columns) at 37˚C in the presence, or absence (C:
control) of the indicated concentrations of drugs. The percentage of
cells in each category was determined by morphologic analysis, scoring
at least 2,000 cells/slide to identify those containing mitotic figures or
2 nuclei. Results were expressed as % of mitotic (A) or BNCs (B) in
drug-treated cultures divided by the % of mitotic (C: 0.42±0.08%) or
BNCs (C: 2.73±0.57%) in vehicle-treated controls. Bars: means±SD
(n=3). ap<0.05, smaller than control; bp<0.01 and cp<0.025, greater
than respective controls.
Figure 12. Comparison of the effects of the antiproliferative KU-69
compound, vincristine (VCR) and taxol on the frequency of
multinucleated (MULTI) cells (A) and micronuclei (MNi) (B) in L1210
tumor cells in vitro. L1210 cells were incubated in triplicate for 24 (open
columns) and 48 h (closed columns) at 37˚C in the presence or absence
(C: control) of the indicated concentrations of drugs. The percentage of
cells in each category was determined by morphological analysis,
scoring at least 2,000 cells/slide to identify those containing 3-4 nuclei
or MNi. A: Results were expressed as % of MULTI cells in drug-treated
cultures divided by the % of MULTI cells in vehicle-treated controls (C:
0.34±0.07%). B: Results were expressed as % of vehicle- (C:
0.06±0.01%) or drug-treated cells with MNi. Bars: means±SD (n=3).
aNot different from control; bp<0.005, greater than respective controls.
member polycyclic annulated indole library (1-9). This is the
first library of annulated indoles reported in the literature to
date and it is the first to employ indole arynes as a strategic
device. The present study is the first to report that, out of the
66 newly-synthesized 6,7-annulated-4-substituted indoles
tested for their bioactivity, 8 compounds from the Buchwald-
Hartwig cross-coupled products and 1 compound from the
Suzuki-Miyaura series exhibited interesting antitumor effects
in L1210 cells with antiproliferative IC50 activities ranging
between 0.5-4 μM after 4 days in culture. The results are
encouraging, given the fact that strong anti-cancer
compounds were discovered among a relatively small library
of annulated indoles synthesized. The antitumor activities of
such 6,7-annulated-4-substituted indoles open the possibility
of designing new anticancer drugs based on this framework.
An interesting structure-activity relationship (SAR) emerges
with these entities. It appears that in annulated bicyclic
structures, those with a –CH2 bridge generally showed
higher activity than those with an oxygen bridge, and that
fluorinated benzylic amines gave the highest antiproliferative
activity. For example, substituting an oxygen bridge for a
methylene bridge (KU-72 vs. KU-69), reduced the
antiproliferative activity at day 4 by a factor of 4 (Figure 2).
Removing the ortho-fluoro substituent in KU-69 reduced the
antiproliferative activity only by a factor of about 2 (KU-69
vs. KU-87) (Figure 2). Also, changing the methyl-amine to
an ethyl-amine (KU-87 vs. KU-95) only slightly decreased
the antiproliferative activity (Figure 2). However, changing
a benzyl-amine to a phenethylamine (KU113) reduced the
antiproliferative activity from KU-72 by a factor of 2 and
from KU-69 by a factor of 4 (Figure 2). Within the series of
3 cyclic amino products (KU-96, KU-80 and KU-70),
marginally increased antiproliferative activity seems to
correlate with smaller ring size (Figure 2). Since KU-69 has
the best antiproliferative IC50 value at day 4, a quantitative
SAR study is planned for this compound based, in part, on
Topliss considerations. The Topliss correlation predicts the
effect of having lipophilic/hydrophilic groups and electron-
donating/electron-withdrawing groups at various positions
(ortho, meta and para) on an isolated benzene ring. For
example, it is predicted that by having a 3,4-dichloro
substitution pattern on the benzylic amine of KU-69, the
antiproliferative of this compound should increase.
Unfortunately, the magnitude of such increased bioactivity
cannot be predicted. In addition, to investigate the effect of
N-alkyl substitution, we plan of replacing the N-methyl
group with other alkyl groups of various lengths and
branching patterns. 
The concentration-dependent inhibitions of L1210 tumor
cell proliferation by the annulated indoles are always more
pronounced at 4 rather than 2 days, suggesting that the
effectiveness of these bioactive compounds is a combination
of drug concentration and duration of action. Although it
may be somewhat misleading to compare biological
responses measured at very different times, the
concentration-dependent inhibitions of DNA synthesis by
KU-70 and KU-80 (Figure 6) suggest that the ability of these
compounds to prevent tumor cells from synthesizing
macromolecules at 3 h may play a role in their
antiproliferative activity at days 2 and 4 (Figure 4). In
accordance with the effects of established anticancer drugs
used as positive controls, concentrations of KU-80, higher
than those sufficient to inhibit tumor cell proliferation must
be used to inhibit DNA synthesis or maximally induce DNA
fragmentation. Such apparent discrepancy may simply be
due to different experimental conditions and cellular
responses to various periods of drug exposure: the rate of
DNA synthesis over 30 min is inhibited in cells treated for
only 3 h with KU-80 or Mitox and DNA fragmentation
occurs 24 h after treatment with KU-80, Mitox or DAU,
whereas the more spectacular inhibitions of L1210 tumor cell
proliferations are the result of 2- and 4-day long drug
treatments. However, in spite of their excellent
antiproliferative IC50 values at day 4, KU-69, KU-87 and
KU-95 have the worst antiproliferative activities of the series
at day 2 in relation with their weak abilities to inhibit DNA
synthesis at 3 h and induce DNA fragmentation at 24 h.
Conversely, the annulated indoles that have the most
effective antitumor effects over shorter periods of time, such
as KU-80 and KU-96, are some of the most potent inhibitors
of DNA synthesis and inducers of DNA fragmentation within
3-24 h in relation with the fact that they already have some
of the best antiproliferative activities at day 2. In contrast to
slow-acting compounds like KU-69, KU-87 and KU-95 that
might need more than 2 days to fully express their superior
antiproliferative activities, therefore, it is postulated that the
annulated indoles that are the most effective in short-term
antitumor assays, such as KU-70, KU-80, KU-96 and KU-
191, might have a more rapid mechanism of action and need
less time to interact with and be incorporated into cells,
undergo eventual metabolic activation, reach crucial cellular
targets, and trigger various inhibitory pathways that finally
damage and kill tumor cells. 
FDA-approved Mitox is a synthetic anthracenedione
related to DAU but less cardiotoxic. Besides targeting the
DNA topoisomerase II enzyme to induce DNA damage, the
mechanism of action of anthracycline-type antitumor drugs
involves intercalation of the planar aglycone moiety into
DNA to disrupt DNA replication and transcription (23). The
9-anilinoacridine drug m-AMSA is known to quench EB-
DNA fluorescence and its anti-leukemic activity requires
intercalative DNA binding (24, 25). Although alternative
binding modes that include single-stranded DNA have also
been proposed, the antitumor antibiotic Act-D blocks RNA
polymerase and transcription by binding to double-stranded
DNA. Act-D complexes with duplex DNA by intercalation
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of its planar aromatic rings between adjacent base pairs of
the double helix, the dinucleotide site GpC exhibiting an
especially high binding affinity for Act-D (26). In addition,
m-AMSA preferentially targets and inhibits DNA
topoisomerase II activity, whereas Act-D is likely a dual
inhibitor of DNA topoisomerase I and II enzymes (27-29).
Hence, the present EB results are consistent with the fact that
Mitox (8 μM), Act-D (50 μM) and m-Amsa (125 μM) are
DNA-reactive agents that intercalate into DNA and cause
crosslinks and strand breaks. However, the observation that a
single KU-80 compound is capable of directly binds to
purified DNA to inhibit by 11.4-52.6% the fluorescence of
the EB-DNA complex in a concentration-dependent manner
over the 50-1,953 μM range (Figure 7), while the 8 other
antiproliferative annulated indoles have no, or much weaker
inhibitory effects in such DNA binding cell-free assay,
suggests that most of the antiproliferative 6,7-annulated-4-
substituted indoles synthesized are unlikely to directly target
cellular DNA to exert their antitumor activities. 
In contrast to the early cleavage of DNA into large 
50-300 kbp fragments, an initial signaling event that may
induce tumor cells treated with relatively low concentrations
of DNA-damaging anticancer drugs to commit apoptosis, the
secondary endonucleolytic degradation of DNA at
internucleosomal linker sites to produce small 180-200 bp
mono- and oligonucleosomal fragments at 24 h, is a late
marker concurrent with morphological evidence of apoptosis
(30). Upstream of internucleosomal DNA fragmentation,
activation of the caspase cascade induces the proteolytic
cleavage of a wide range of substrates. For instance, effector
caspase-3 cleaves and inactivates the inhibitor of caspase-
activated DNase, thus releasing active endonucleases that
translocate into the nucleus to achieve internucleosomal
DNA fragmentation (30). Antiproliferative concentrations of
annulated indoles, especially KU-80, KU-96 and KU-191, all
induce DNA fragmentation in L1210 cells at 24 h (Figures
8 and 9), suggesting that the ability of 6,7-annulated-4-
substituted indoles to trigger apoptosis may play a significant
role in their molecular mechanism of antitumor activity. This
hypothesis is substantiated by the finding that KU-80 and
KU-96 also induce a time-dependent increase of caspase-3
activity (Figure 10), which peaks at 6 h in L1210 cells and
thus precedes the fragmentation of radiolabeled DNA and the
appearance of apoptotic cells with 5 or more small nuclear
structures detected at 24 h. Since apoptosis is an active ATP-
driven and cell-cycle phase-specific process that requires the
expression of specific genes, the synthesis of new RNA and
proteins, and the activation of caspases, non-caspase
proteases and nucleases, inhibition of such active
mechanisms can prevent apoptosis (18-20). The discrepancy
between the time-dependent activations of effector caspase-
3 by annulated indoles, Mitox and DAU in L1210 cells might
be due to differences in concentrations and mechanisms of
action. Since KU-80 and KU-96 are tested at much higher
concentrations than Mitox and DAU, it is possible that, even
though they are increasingly cytostatic, the 62.5 μM
concentrations of antiproliferative annulated indoles might
inhibit DNA (Figures 5 and 6) and other macromolecule
syntheses to such excessive degree and become so cytotoxic
over time as to abolish their own ability to sustain the
activation of caspase-3 (Figure 10) beyond 6-12 h (18-20).
Even though most antiproliferative annulated indoles do not
directly bind to DNA, the abilities of these antitumor
compounds to interact with maintenance enzymes or
regulatory proteins and indirectly cause high molecular
weight DNA-strand breaks, crosslinks or chromosome
aberrations and cytokinesis disruption remain to be
determined. Therefore, it is rather premature to speculate on
the nature of the primary molecular targets, massive
damaging events and nuclear signals that induce tumor cells
treated with antiproliferative annulated indoles to undergo
mitotic disruption and apoptotic DNA degradation and
nuclear fragmentation. The fact that 4 μM KU-69 is capable
of causing 11.1- and 7.0-fold increases in the number of
L1210 cells that display mitotic figures at 24 and 48 h
(Figure 11) suggests an ability to disrupt microtubule
kinetics. But 4 μM KU-69 cannot achieve the dramatic 54.1-
and 22.5-fold increases in the mitotic index of L1210 cells
caused by much smaller 0.05 μM concentrations of
antimitotic VCR and taxol at 48 h, suggesting that this
compound is not a potent mitotic spindle poison. Even
though annulated indoles might weakly interact with tubulin
and alter the polymerization/depolymerization of
microtubules, these compounds are likely to target other
molecular events in order to elicit their antiproliferative
activity. For instance, increasingly antiproliferative 0.64-25
μM concentrations of KU-69 might trigger some genotoxic
effects that induce chromosomal aberration, disrupt
chromosomal segregation and block cytokinesis to
substantially increase the levels of BNCs, MULTI cells and
MNi in L1210 tumor cells at 24-48 h, the magnitudes of
these responses often matching or even surpassing those
induced by VCR and taxol (Figures 11 and 12). BNCs
indicate that cytokinesis is inhibited following nuclear
division (21). MULTI cells may follow if BNCs re-enter the
cell cycle and escape further cytokinesis. The micronucleus
test is an indicator of drug-induced chromosomal damage
and aberration as such MNi structures generally form during
the metaphase/anaphase transition of mitosis when a whole
lagging chromosome or an acentric chromosome fragment
resulting from a clastogenic or mutagenic event fail to
integrate into the daughter nuclei (21). However,
chromosome aberration and non-disjunction/missegregation
might be the consequence of prolonged drug-induced mitotic
disruption and might be responsible for cellular inability to
undergo cytokinesis after regression of the cleavage furrow
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(31). If completion of cytokinesis requires accurate
chromosome segregation, it is possible that KU-69 treatment
induces chromosome aberration and missegregation to
increase the frequency of BNCs, MULTI cells and MNi.
NPBs between nuclei in BNCs originate from dicentric
chromosomes in which the centromeres have been pulled to
the opposite poles of the cell at anaphase and are indicative
of DNA misrepair, chromosome re-arrangement or telomere
end-fusions (21). NPBs may break to form MNi. NPBs,
which are correlated with MNi frequency in BNCs, are thus
biomarkers of dicentric chromosomes and might provide
indirect evidence of KU-69-induced genome damage
resulting from misrepaired DNA breaks. NBUDs occur
during S-phase and form MNi that are still linked to the
nucleus by a narrow or wide stalk of nucleoplasmic material
depending on the stage of the budding process. Amplified
and/or excess DNA is selectively localized to specific sites
at the periphery of the nucleus and is eliminated via nuclear
budding to form MNi during S phase. Hence,
antiproliferative annulated indoles and drugs that inhibit
DNA synthesis like hydroxyurea might increase the rate of
elimination of amplified DNA and possibly DNA-repair
complexes via nuclear budding (32, 33). Further SAR studies
are required to identify more potent antitumor lead
compounds and characterize their molecular targets and
mechanisms of action. This series of synthetic 6,7-annulated-
4-substituted indoles has also been submitted to the
Molecular Library Screening Center Network (MLSCN) to
assess their bioactivity in a wide range of cell-based and
other biological assays.
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